# Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

> **NCT03361436** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Liposarcoma
- Malignant Abdominal Neoplasm
- Malignant Retroperitoneal Neoplasm
- Malignant Scrotal Neoplasm
- Malignant Solid Neoplasm
- Malignant Spermatic Cord Neoplasm

## Interventions

- **DRUG:** Eribulin Mesylate
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03361436
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-19
- **Primary completion:** 2023-02-14
- **Final completion:** 2033-04-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361436, "Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03361436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*